The main baseline parameters of patients included in the study.
| Parameters | Study cohort (n = 82) |
|---|---|
| Sex | n (%) |
| male | 39 (47.6) |
| female | 43 (52.4) |
| Age at initial diagnosis, median (range), years | 47 (24–83) |
| Age at the start of lorlatinib, median (range), years | 51 (25–85) |
| ECOG PS at lorlatinib initiation | n (%) |
| 0/1 | 66 (80.5) |
| 2 | 16 (19.5) |
| Smoking history | n (%) |
| Never smoker | 54 (65.9) |
| Former smoker | 23 (28.0) |
| Current smoker | 5 (6.1) |
| Histology | n (%) |
| Adenocarcinoma | 80 (97.6) |
| Non-adenocarcinoma NSCLC | 2 (2.4) |
| Method of ALK identification | n (%) |
| PCR or NGS | 36 (43.9) |
| FISH | 37 (45.1) |
| IHC | 9 (11.0) |
| Stage of disease at initial diagnosis | n (%) |
| I–II | 5 (6.1) |
| III–IV | 77 (93.9) |
| Brain metastases at lorlatinib initiation | n (%) |
| Yes | 65 (79.3) |
| No | 17 (20.7) |
| Number of brain metastases at lorlatinib initiation | n (% of total cases with brain metastases) |
| Single | 11 (16.9) |
| Multiple | 54 (83.1) |
| Local brain-directed therapy before the start of lorlatinib | n (% of total cases with brain metastases) |
| Stereotactic radiosurgery | 22 (33.8) |
| Whole brain radiation therapy | 14 (21.5) |
| None | 29 (44.6) |
| Chemotherapy in prior lines | n (%) |
| Yes | 57 (69.5) |
| No | 25 (30.5) |
| Number of prior ALK TKIs | n (%) |
| 1 (with crizotinib) | 44 (53.7) |
| 1 (with second-generation ALK TKI) | 18 (22.0) |
| 2 | 16 (19.5) |
| 3 | 4 (4.9) |
| Last therapy before lorlatinib | n (%) |
| Crizotinib | 44 (53.7) |
| Ceritinib | 22 (26.8) |
| Brigatinib | 11 (13.4) |
| Alectinib | 5 (6.1) |
| Response to prior TKI | n (%) |
| ≥ 4 and < 12 months | 31 (37.8) |
| ≥ 12 months | 51 (62.2) |
| Line of lorlatinib therapy | n (%) |
| 2 | 20 (24.4) |
| 3 | 37 (45.1) |
| 4 | 15 (18.3) |
| 5 | 10 (12.2) |
ALK: anaplastic lymphoma kinase; ECOG PS: Eastern Cooperative Oncology Group Performance Status; FISH: fluorescence in situ hybridization; IHC: immunohistochemistry; NGS: next-generation sequencing; NSCLC: non-small cell lung cancer; PCR: polymerase chain reaction; TKI: tyrosine kinase inhibitor.